Neuromonitoring for Hypoxic-Ischemic Brain Injury
(DIFFUSION Trial)
Trial Summary
What is the purpose of this trial?
This trial evaluates how well oxygen gets from the blood into the brain in patients who have had a cardiac arrest. It focuses on patients with brain injury due to lack of oxygen, checking both blood flow and oxygen movement into brain cells, as well as looking at markers for brain injury and inflammation.
Will I have to stop taking my current medications?
The trial excludes participants who are currently using or are expected to use anticoagulant or antiplatelet medications, so you would need to stop these medications to participate.
What data supports the effectiveness of the treatment Neuromonitoring for Hypoxic-Ischemic Brain Injury?
Research shows that neuromonitoring can help detect early changes in brain function, allowing for timely treatment to prevent further brain damage. Techniques like intracranial pressure monitoring and EEG are used to monitor brain health in critical care, which can improve outcomes in patients with brain injuries.12345
Is neuromonitoring safe for humans?
How is the treatment Neuromonitoring different from other treatments for hypoxic-ischemic brain injury?
Neuromonitoring is unique because it involves continuous observation of brain functions using techniques like intracranial pressure measurement and EEG monitoring, which help detect subtle changes in brain physiology early. Unlike other treatments, it focuses on real-time monitoring to prevent further brain damage by providing immediate data that can guide therapeutic decisions.135910
Eligibility Criteria
This trial is for adults over 19 who've had a cardiac arrest lasting more than 10 minutes and are in a coma or have severe brain function impairment. They must be able to receive invasive monitoring within 72 hours of the event. People with blood clotting issues, on certain blood thinners, or with past severe brain injuries or strokes can't participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Neuromonitoring
Neuromonitoring is placed after cardiac arrest, and various evaluations are conducted including blood gas analysis and microdialysis measures.
Follow-up
Participants are monitored for clinical outcomes, including cerebral performance category, at 6 months post-arrest.
Treatment Details
Interventions
- Neuromonitoring
Neuromonitoring is already approved in United States, European Union, Canada for the following indications:
- Monitoring of intracranial pressure and cerebral perfusion in critically ill patients
- Diagnosis and management of seizures and status epilepticus
- Assessment of brain death
- Monitoring of brain function in patients with traumatic brain injury
- Diagnosis and management of cerebral vasospasm
- Assessment of cerebral autoregulation
- Monitoring of intracranial pressure and cerebral perfusion in critically ill patients
- Diagnosis and management of seizures and status epilepticus
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of British Columbia
Lead Sponsor